PremiumThe FlyMural Oncology price target lowered to $6 from $18 at H.C. Wainwright Mural Oncology halting progress of nemvaleukin trial in ovarian cancer Mural Oncology downgraded to Hold from Buy at JonesResearch PremiumRatingsPromising Outlook for Mural Oncology: Buy Rating Driven by Nemvaleukin’s Potential and Strategic Trials Mural Oncology Highlights 2024 Financial Results and Strategic Focus Mural Oncology reports Q4 EPS ($2.01), consensus ($1.96) PremiumThe FlyMural Oncology files $300M mixed securities shelf Mural Oncology reports Q3 EPS ($1.87), consensus ($1.95) MURA Earnings this Week: How Will it Perform? 
